<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128462</url>
  </required_header>
  <id_info>
    <org_study_id>MNK61053106</org_study_id>
    <secondary_id>2019-001635-31</secondary_id>
    <nct_id>NCT04128462</nct_id>
  </id_info>
  <brief_title>MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia Associated With an Episode of Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with cirrhosis and hepatic encephalopathy who are in the hospital.&#xD;
      This means they have a high ammonia level which is affecting their brain function.&#xD;
&#xD;
      All patients will receive the standard of (regular) care. Each will have an equal chance&#xD;
      (like flipping a coin) of receiving the experimental drug or placebo along with the standard&#xD;
      care.&#xD;
&#xD;
      Each patient will have tests during the first 24 hours, receive treatment for up to 5 days,&#xD;
      and have 30 days of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business Decision&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a clinical response at Day 5</measure>
    <time_frame>at Day 5 (within 36 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients discharged 30 days after end of treatment.</measure>
    <time_frame>at Day 35 (within 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients readmitted to the hospital due to overt hepatic encephalopathy (OHE) 30 days after discharge.</measure>
    <time_frame>30 days after discharge (within 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events or deaths during the study</measure>
    <time_frame>within 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>MNK6105 + SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:&#xD;
Loading dose: 20 g infused over 6 hours&#xD;
Intermediate dose: 15 g infused over 18 hours&#xD;
Maintenance dose: 15 g infused over 24 hours for up to 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SoC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNK-6105</intervention_name>
    <description>L-Ornithine Phenylacetate for IV infusion</description>
    <arm_group_label>MNK6105 + SoC</arm_group_label>
    <other_name>L-Ornithine Phenylacetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for IV infusion</description>
    <arm_group_label>Placebo + SoC</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Lactulose Â± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.</description>
    <arm_group_label>MNK6105 + SoC</arm_group_label>
    <arm_group_label>Placebo + SoC</arm_group_label>
    <other_name>SoC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included, a patient must:&#xD;
&#xD;
          -  Be the age of majority in their country (considered an adult)&#xD;
&#xD;
          -  Be male or non-pregnant, non-lactating female&#xD;
&#xD;
          -  Have OHE (Stage 2, 3, or 4) as a complication of cirrhosis&#xD;
&#xD;
          -  Have been hospitalized within 24 hours before start of infusion (SOI)&#xD;
&#xD;
          -  Receive at least 6 hours of SoC treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if they have inadequate renal function or any other disease,&#xD;
        laboratory value, or condition (including allergy, drug use or treatments) that per&#xD;
        protocol or in the opinion of the investigator, might increase the risk of compromising:&#xD;
&#xD;
          1. health or well-being of the patient&#xD;
&#xD;
          2. safety of study staff&#xD;
&#xD;
          3. analysis of results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overt HE diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

